Milenperone

Milenperone

SCHEMBL121986

O=C(c1ccc(F)cc1)C1CCN(CCCn2c(=O)[nH]c3cc(Cl)ccc32)CC1

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.58
CYP1A2 P05177 4/20 0.58
CYP3A4 P08684 4/20 0.58
HTR2A P28223 4/20 0.58
DRD2 P14416 3/20 0.58
LMNA P02545 3/20 0.58
MEN1 O00255 2/20 0.58
HTR1A P08908 2/20 0.58
ADRA2B P18089 2/20 0.58
ADRA2C P18825 2/20 0.58
HTR2C P28335 2/20 0.58
SLC6A4 P31645 2/20 0.58
ADRA1A P35348 2/20 0.58
HRH1 P35367 2/20 0.58
DRD3 P35462 2/20 0.58
HTR2B P41595 2/20 0.58
SLC6A3 Q01959 2/20 0.58
KMT2A Q03164 2/20 0.58
KCNH2 Q12809 2/20 0.58
USP2 O75604 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Milenperone SCHEMBL29710910 1.00 CYP2D6 (0.58) CYP2D6CYP1A2CYP3A4HTR2ADRD2
SCHEMBL11708162 0.94 HTR2A (0.64) CYP2D6CYP1A2CYP3A4HTR2ADRD2
SCHEMBL11713024 0.93 CYP3A4 (0.57) CYP2D6CYP1A2CYP3A4HTR2ADRD2
SCHEMBL11708157 0.90 HTR2A (0.58) CYP2D6CYP1A2CYP3A4HTR2ADRD2
SCHEMBL3404250 0.90 HTR2A (0.58) CYP2D6CYP1A2CYP3A4HTR2ADRD2
SCHEMBL11707407 0.89 HTR2A (0.57) CYP2D6CYP1A2CYP3A4HTR2ADRD2
SCHEMBL11708736 0.87 CYP3A4 (0.55) CYP2D6CYP1A2CYP3A4HTR2ADRD2
SCHEMBL11708317 0.87 HTR2A (0.64) CYP2D6CYP1A2CYP3A4HTR2ADRD2
Declenperone SCHEMBL2112237 0.86 HTR2A (0.69) CYP2D6CYP1A2CYP3A4HTR2ADRD2
SCHEMBL11707801 0.86 HTR2A (0.58) CYP2D6CYP1A2CYP3A4HTR2ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931320-B1 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME FLAMEL IRELAND LTD (IE) 2022-06-15 EP claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
US-20090220611-A1 Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same FLAMEL TECHNOLOGIES, S.A. (FR) 2009-09-03 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
EP-1931320-A2 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME Flamel Technologies (FR) 2008-06-18 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
WO-2007036671-A2 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME FLAMEL TECHNOLOGIES (FR) 2007-04-05 WO claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
EP-1044023-B1 A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA LUITPOLD PHARM INC (US) 2005-05-25 EP claimed
US-6197764-B1 COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS PROTARGA, INC. 2001-03-06 US claimed
EP-1044023-A1 A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA Protarga Inc. (US) 2000-10-18 EP claimed
US-5955459-A Fatty acid-antipsychotic compositions and uses thereof NEUROMEDICA, INC. (US) 1999-09-21 US claimed
WO-1999026661-A1 A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA PROTARGA INC. (US) 1999-06-03 WO claimed
US-4035369-A 1-Benzazolylalkyl-4-substituted-piperidines JANSSEN PHARMACEUTICA N.V. (BE) 1977-07-12 US claimed